Assessment of safety, efficacy, PK and PD of BG9924 in RA patients who have had an inadequate response to conventional DMARD therapy

Trial Profile

Assessment of safety, efficacy, PK and PD of BG9924 in RA patients who have had an inadequate response to conventional DMARD therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Baminercept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms RESPOND; RESPOND-EXT
  • Sponsors Biogen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Oct 2009 Preliminary results were presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals.
    • 09 Jan 2009 Extension study status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top